본문 바로가기
KERD
논문KCI 등재

Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment

신경환|김자영|박영희|정소연|이은숙|박인혜|이근석|노정실|김태현|김연주|좌은진
대한암학회 (Korean Cancer Association)|2016.10|Cancer Research and Treatment|제48권 제4호|pp. 1363-1372

0

조회

0

다운로드

0

인용

0

참고문헌

키워드

Breast neoplasmsNeoadjuvant chemotherapyLocal neoplasm recurrenceMolecular subtypeIpsilateral breast tumor recurrence
주제분류의학일반

초록

Purpose The purpose of this study is to determine whether breast cancer subtype can affect locoregional recurrence (LRR) and ipsilateral breast tumor recurrence (IBTR) after neoadjuvant chemotherapy (NAC) and breast-conserving therapy (BCT). Materials and Methods We evaluated 335 consecutive patients with clinical stage II-III breast cancer who received NAC plus BCT from 2002 to 2009. Patients were classified according to six molecular subtypes: luminal A (hormone receptor [HR]+/HER2–/Ki-67 < 15%, n=113), luminal B1 (HR+/HER2–/Ki-67  15%, n=33), luminal B2 (HR+/HER2+, n=83), HER2 with trastuzumab (HER2[T+]) (HR–/HER2+/use of trastuzumab, n=14), HER2 without trastuzumab (HER2[T–]) (HR–/HER2+, n=31), and triple negative (TN) (HR–/HER2–, n=61). Results After a median follow-up period of 7.2 years, 26 IBTRs and 37 LRRs occurred. The 5-year LRR-free survival rates were luminal A, 96.4%; B1, 93.9%; B2, 90.3%; HER2(T+), 92.9%; HER2(T–), 78.3%; and TN, 79.6%. The 5-year IBTR-free survival rates were luminal A, 97.2%; B1, 93.9%; B2, 92.8%; HER2(T+), 92.9%; HER2(T–), 89.1%; and TN, 84.6%. In multivariate analysis, HER2(T–) (IBTR: hazard ratio, 4.2; p=0.04 and LRR: hazard ratio, 7.6; p < 0.01) and TN subtypes (IBTR: hazard ratio, 6.9; p=0.01 and LRR: hazard ratio, 8.1; p < 0.01) were associated with higher IBTR and LRR rates. A pathologic complete response (pCR) was found to show correlation with better LRR and a tendency toward improved IBTR controls in TN patients (IBTR, p=0.07; LRR, p=0.03). Conclusion The TN and HER2(T–) subtypes predict higher rates of IBTR and LRR after NAC and BCT. A pCR is predictive of improved IBTR or LRR in TN subtype.

Abstract

Purpose The purpose of this study is to determine whether breast cancer subtype can affect locoregional recurrence (LRR) and ipsilateral breast tumor recurrence (IBTR) after neoadjuvant chemotherapy (NAC) and breast-conserving therapy (BCT). Materials and Methods We evaluated 335 consecutive patients with clinical stage II-III breast cancer who received NAC plus BCT from 2002 to 2009. Patients were classified according to six molecular subtypes: luminal A (hormone receptor [HR]+/HER2–/Ki-67 < 15%, n=113), luminal B1 (HR+/HER2–/Ki-67  15%, n=33), luminal B2 (HR+/HER2+, n=83), HER2 with trastuzumab (HER2[T+]) (HR–/HER2+/use of trastuzumab, n=14), HER2 without trastuzumab (HER2[T–]) (HR–/HER2+, n=31), and triple negative (TN) (HR–/HER2–, n=61). Results After a median follow-up period of 7.2 years, 26 IBTRs and 37 LRRs occurred. The 5-year LRR-free survival rates were luminal A, 96.4%; B1, 93.9%; B2, 90.3%; HER2(T+), 92.9%; HER2(T–), 78.3%; and TN, 79.6%. The 5-year IBTR-free survival rates were luminal A, 97.2%; B1, 93.9%; B2, 92.8%; HER2(T+), 92.9%; HER2(T–), 89.1%; and TN, 84.6%. In multivariate analysis, HER2(T–) (IBTR: hazard ratio, 4.2; p=0.04 and LRR: hazard ratio, 7.6; p < 0.01) and TN subtypes (IBTR: hazard ratio, 6.9; p=0.01 and LRR: hazard ratio, 8.1; p < 0.01) were associated with higher IBTR and LRR rates. A pathologic complete response (pCR) was found to show correlation with better LRR and a tendency toward improved IBTR controls in TN patients (IBTR, p=0.07; LRR, p=0.03). Conclusion The TN and HER2(T–) subtypes predict higher rates of IBTR and LRR after NAC and BCT. A pCR is predictive of improved IBTR or LRR in TN subtype.

참고문헌 (28)

  1. Schwartz GF, "Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast", Cancer, 73, pp.362~369 (1994)
  2. van der Hage JA, "Preoperative chemotherapy in primary operable breast cancer : results from the European Organization for Research and Treatment of Cancer trial 10902", J Clin Oncol, 19, pp.4224~4237 (2001)
  3. Rastogi P, "Preoperative chemotherapy : updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27", J Clin Oncol, 26, pp.778~785 (2008)
  4. Mieog JS, "Neoadjuvant chemotherapy for operable breast cancer", Br J Surg, 94, pp.1189~1200 (2007)
  5. Min SY, "Locoregional recurrence of breast cancer in patients treated with breast conservation surgery and radiotherapy following neoadjuvant chemotherapy", Int J Radiat Oncol Biol Phys, 81, pp.697~705 (2011)
  6. Perou CM, "Molecular portraits of human breast tumours", Nature, 406, pp.747~752 (2000)
  7. Sorlie T, "Repeated observation of breast tumor subtypes in independent gene expression data sets", Proc Natl Acad Sci U S A, 100, pp.8418~8423 (2003)
  8. Brenton JD, "Molecular classification and molecular forecasting of breast cancer : ready for clinical application?", J Clin Oncol, 23, pp.7350~7360 (2005)
  9. Carey LA, "Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study", JAMA, 295, pp.2492~2502 (2006)
  10. Nguyen PL, "Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy", J Clin Oncol, 26, pp.2373~2378 (2008)
  11. Albain KS, "Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy : a retrospective analysis of a randomised trial", Lancet Oncol, 11, pp.55~65 (2010)
  12. Mamounas EP, "Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer : results from NSABP B-14 and NSABP B-20", J Clin Oncol, 28, pp.1677~1683 (2010)
  13. Lee KS, "Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer:a phase II trial", Invest New Drugs, 28, pp.83~90 (2010)
  14. Lee KS, "A randomized phase-III trial of docetaxel", capecitabine versus doxorubicin, III breast cancer, pp.Breast Cancer Res Treat, 2008[DOI]
  15. Allred DC, "Prognostic and predictive factors in breast cancer by immunohistochemical analysis", Mod Pathol, 11, pp.155~168 (1998)
  16. Wolff AC, "Recommendations for human epidermal growth factor receptor 2 testing in breast cancer : American Society of Clinical Oncology", College of American Pathologists clinical practice guideline update, 2013, pp.31, 3997~4013
  17. Dowsett M, "Assessment of Ki67 in breast cancer : recommendations from the International Ki67 in Breast Cancer working group", J Natl Cancer Inst, 103, pp.1656~1664 (2011)
  18. Goldhirsch A, "Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011", Ann Oncol, 22, pp.1736~1747 (2011)
  19. Stuart-Harris R, "Proliferation markers and survival in early breast cancer : a systematic review and meta-analysis of 85 studies in 32, 825 patients", Breast, 17, pp.323~334 (2008)
  20. Sorlie T, "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", Proc Natl Acad Sci U S A, 98, pp.10869~10874 (2001)
  21. 노재명, "Exome sequencing in a breast cancer family without BRCA mutation", Radiation oncology journal, 33(2), pp.149~154 (2015), 대한방사선종양학회
  22. Arvold ND, "Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy", J Clin Oncol, 29, pp.3885~3891 (2011)
  23. Vargo JA, "Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer", Oncology, 80, pp.341~349 (2011)
  24. Meyers MO, "Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer", Ann Surg Oncol, 18, pp.2851~2857 (2011)
  25. Caudle AS, "Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy", Breast Cancer Res, 14, pp.83~ (2012)
  26. Esserman LJ, "Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles : results from the I-SPY 1 TRIAL(CALGB 150007", 150012;ACRIN 6657), 2012, pp.132, 1049~1062
  27. Esserman LJ, "Pathologic complete response predicts recurrencefree survival more effectively by cancer subset : results from the I-SPY 1 TRIAL--CALGB 150007", 150012, ACRIN 6657, 2012, pp.30, 3242~3249
  28. 유창훈, "Impact of Immunohistochemistry-Based Molecular Subtype on Chemosensitivity and Survival in Patients with Breast Cancer Following Neoadjuvant Chemotherapy", Journal of Breast Cancer, 15(2), pp.203~210 (2012), 한국유방암학회[DOI]

관련 논문AI추천

Prognostic Factors in Patients with Locally Advanced Breast Cancer Treated by Neoadjuvant Chemotherapy박민호, 윤정한, 조진성, Min Jaegal, Shin Jae Kang, Young Jae Ryu한국유방암학회 · Journal of Breast Disease2019 · 제7권 제1호Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome권영미, 김병남, 남병호, 노정실, 박인혜, 유지영, 이근석, 이무현, 이은숙, 정소연, Siew Kuan Lim대한암학회 · Cancer Research and Treatment2016 · 제48권 제1호Young Age Is Associated with Increased Locoregional Recurrence in Node-Positive Breast Cancer with Luminal Subtypes강석윤, 강승희, 김상원, 임현이, 전미선, 정용식, 최진혁, 한세환대한암학회 · Cancer Research and Treatment2017 · 제49권 제2호Are the Outcomes of Breast Conservation Surgery Inferior to Those of Mastectomy in Patients with Stage II-IIIA Triple-Negative Breast Cancer?김지연, 김현열, 이석원, Chang Shin Jung, Dong Il Kim, Hyun-June Paik, Seok-Kyung Kang, Seungju Lee, Youngtae Bae, Youn Joo Jung한국유방암학회 · Journal of Breast Disease2021 · 제9권 제2호Breast Conservation Therapy versus Mastectomy in Patients with T1-2N1 Triple-Negative Breast Cancer: Pooled Analysis of KROG 14-18 and 14-23박원, 김규보, 김대용, 김수산, 김지영, 김진호, 김진희, 김태현, 박혜진, 신경환, 안승도, 최두호대한암학회 · Cancer Research and Treatment2018 · 제50권 제4호Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period남석진, 박연희, 안진석, 임영혁, 조수연, 조은윤, 최미선대한병리학회 · Journal of Pathology and Translational Medicine2017 · 제51권 제1호

이 간행물의 다른 논문 (29건)

Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal TumorJie Zheng, Seiichi Hirota, Akira Sawaki, Li-Tzong Chen, Lin Shen, 구동회, 강윤구, 류민희, 김경미, 양한광, Chun-Nan Yeh, Chin-Yuan Tzen, Toshirou Nishida, Bo Zhangpp. 1155-1166Predictors of Distant Metastasis after Radical Surgery Followed by Postoperative Radiotherapy with or without Chemotherapy for Oropharyngeal Cancer김연실, 이연수, 김지윤, 이윤희, 장지현, 강진형, 유이령, 정미주pp. 1167-1176East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL)Ekaterine Alexandris, Pablo Lee, Annamaria Hayden Zimmermann, 강진형, 조은경, Jin-Yuan Shih, 박근칠, Mauro Orlando, 김주항, Tarun Puripp. 1177-1186Radiation Therapy Alone in cT1-3N0 Non-small Cell Lung Cancer Patients Who Are Unfit for Surgical Resection or Stereotactic Radiation Therapy: Comparison of Risk-Adaptive Dose Schedules오동률, 표홍렬, 조원경, 안용찬, 노재명pp. 1187-1195Overexpression of Endoplasmic Reticulum Oxidoreductin 1-α (ERO1L) Is Associated with Poor Prognosis of Gastric Cancer설소영, 윤선옥, 홍순원, 김종원, 최승호, 조재용, 김철, 임재윤pp. 1196-1209
원문 보기